Faisal Khurshid

Annabel Samimy

Brandon Folkes

Debanjana Chatterjee

Kaveri Pohlman

Leland Gershell

Mayank Mamtani

Ryan Deschner

Serge Belanger

Alexa Deemer

Anthony

Jason Dorr

John Gionco

William Wood

- Tvardi Therapeutics announced that its **Phase 2 REVERT clinical trial** of TTI-101 for idiopathic pulmonary fibrosis (IPF) **did not meet its goals**, as preliminary analysis showed no statistically significant differences between treatment arms and placebo.  **[1563880_e59d6ca9609f4c03b1620deda043a062_0]** 
- Discontinuation rates were notably higher in the TTI-101 treated arms (**56.7%** for 400mg and **62.1%** for 800mg) compared to the placebo group (**10.3%**), primarily driven by gastrointestinal adverse events.  **[1563880_e59d6ca9609f4c03b1620deda043a062_0]** 
- The company remains on track to report preliminary topline data in the **first half of 2026** from a healthy volunteer study on its next-generation STAT3 inhibitor, TTI-109, and from the Phase 2 trial of TTI-101 in hepatocellular carcinoma.  **[1563880_e59d6ca9609f4c03b1620deda043a062_1]** 
- As of **June 30, 2025**, Tvardi reported **$41.0 million** in cash, cash equivalents, and short-term investments, which is expected to fund operations into the **fourth quarter of 2026**.  **[1563880_e59d6ca9609f4c03b1620deda043a062_1]**

Tvardi Therapeutics Provides Update on Preliminary Phase 2 REVERT Trial Data for TTI-101 in IPF

Trevi Therapeutics (TRVI)